-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 4% in the afternoon. Seluotong capsule listing application has been accepted. The agency believes that the market space is broad

Zhitongcaijing·11/20/2026 06:17:02
Listen to the news

The Zhitong Finance App learned that Shenwei Pharmaceutical (02877) rose more than 4% in the afternoon. As of press release, it rose 4.00% to HK$8.44, with a turnover of HK$21.4613 million.

According to the news, Shenwei Pharmaceutical recently announced that its turnover for the first three quarters was 1,731 billion yuan, a year-on-year decrease of 28.3%. Based on product dosage analysis, injectable products, softgel products, granule products and traditional Chinese medicine formula granular products accounted for about 27.6%, 16.7%, 20.3% and 29.0% of the Group's total sales during the period, respectively.

It is worth noting that the Phase III clinical trials of the two exclusive innovative drugs, Xiluotong capsules and JC capsules, have been completed, and production license applications have been accepted; production licenses are expected to be obtained in mid-2027. According to Guoyuan International, vascular dementia is the second most common cause of dementia after Alzheimer's disease. The number of Alzheimer's patients in China exceeded 10 million in 2025, and there are currently no effective treatments. The bank believes that the market space is vast, and Seruotong capsules will be a major variety.